SABCS 2019

Complete Coverage

Removing Barriers to Optimal Breast Cancer Screening May Improve Overall Survival

The researchers looked at what barriers may be contributing to low screening rates among women in Pima County in Southern Arizona.

Combining Navigation With Breast Cancer Survivorship Care Plans

More research is needed to better understand how to optimize the utility of survivorship care plans in patients with breast cancer.

A New Risk Calculator for Radiotherapy in Older Women With Early-Stage Breast Cancer

The ROW risk calculator makes its predictions based on age, comorbidities, functional status, tumor characteristics, and use of radiotherapy.

Metabolic Syndrome May Affect Survival in Postmenopausal Women With Triple-Negative Breast Cancer

Researchers analyzed the association between baseline metabolic syndrome components and survival outcomes in women diagnosed with TNBC.

New Study Looks at Quality of Life With NEPA for CINV in Women With Breast Cancer

Quality of life in patients receiving netupitant/palonosetron chemotherapy induced nausea and vomiting.

Severe Lymphedema After Breast Cancer Surgery Associated With Obesity

Although most cases of lymphedema are mild or moderate, obesity and overweight are common factors in women who experience severe lymphedema and HADS-anxiety after breast cancer surgery.

Symptom Management Is Primary Reason Patients With Breast Cancer Seek Medical Cannabis

A review of the Pennsylvania Medical Marijuana Program defined the symptom profile of patients with breast cancer who sought to use medical marijuana.

Patient-Driven Solutions May Lead to Greater Metastatic Breast Cancer Clinical Trial Participation

More patients living with metastatic breast cancer reportedly would be willing to participate in clinical trials if some changes were made.

Maintenance Durvalumab Shows Activity in Certain Breast Cancer Subgroups

Exploratory subgroup analyses suggest patients with triple-negative breast cancer or PDL1-positive tumors may benefit from maintenance durvalumab.

Subcutaneous Pertuzumab and Trastuzumab Offers Convenience to Patients With HER2-Positive Breast Cancer

A fixed-dose combination of subcutaneous pertuzumab and trastuzumab was found to be noninferior for patients with HER2-positive breast cancer.